Molecular targeted drugs and immunity

Takashi Morisaki, Hideya Ohnishi, Hiroyuki Suzuki, Mitsuo Katano

研究成果: ジャーナルへの寄稿評論記事

抄録

Molecular targeted therapy was largely developed as a consequence of advances in the understanding of the molecular biology of cancer. It was also developed in response to the challenge of optimizing antitumor activity while decreasing nonspecific toxicity. Besides the direct effect on tumor cells, several molecular targeted drugs have been shown to modulate immune responses against cancer including the decreasing number of regulatory T cells (Treg) and activating NK cells. In this review, we focus on recent reports which show the interaction of molecular targeted drugs with immune response. In the near future, combinations of molecular targeted drugs with new immunotherapeutic approaches might become a reality.

元の言語英語
ページ(範囲)291-295
ページ数5
ジャーナルBiotherapy
24
発行部数4
出版物ステータス出版済み - 7 2010

Fingerprint

Immunity
Pharmaceutical Preparations
Molecular Targeted Therapy
Neoplasms
Regulatory T-Lymphocytes
Natural Killer Cells
Molecular Biology

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

これを引用

Morisaki, T., Ohnishi, H., Suzuki, H., & Katano, M. (2010). Molecular targeted drugs and immunity. Biotherapy, 24(4), 291-295.

Molecular targeted drugs and immunity. / Morisaki, Takashi; Ohnishi, Hideya; Suzuki, Hiroyuki; Katano, Mitsuo.

:: Biotherapy, 巻 24, 番号 4, 07.2010, p. 291-295.

研究成果: ジャーナルへの寄稿評論記事

Morisaki, T, Ohnishi, H, Suzuki, H & Katano, M 2010, 'Molecular targeted drugs and immunity', Biotherapy, 巻. 24, 番号 4, pp. 291-295.
Morisaki T, Ohnishi H, Suzuki H, Katano M. Molecular targeted drugs and immunity. Biotherapy. 2010 7;24(4):291-295.
Morisaki, Takashi ; Ohnishi, Hideya ; Suzuki, Hiroyuki ; Katano, Mitsuo. / Molecular targeted drugs and immunity. :: Biotherapy. 2010 ; 巻 24, 番号 4. pp. 291-295.
@article{7a14347ca5224162a62b072fe13c8b7c,
title = "Molecular targeted drugs and immunity",
abstract = "Molecular targeted therapy was largely developed as a consequence of advances in the understanding of the molecular biology of cancer. It was also developed in response to the challenge of optimizing antitumor activity while decreasing nonspecific toxicity. Besides the direct effect on tumor cells, several molecular targeted drugs have been shown to modulate immune responses against cancer including the decreasing number of regulatory T cells (Treg) and activating NK cells. In this review, we focus on recent reports which show the interaction of molecular targeted drugs with immune response. In the near future, combinations of molecular targeted drugs with new immunotherapeutic approaches might become a reality.",
author = "Takashi Morisaki and Hideya Ohnishi and Hiroyuki Suzuki and Mitsuo Katano",
year = "2010",
month = "7",
language = "English",
volume = "24",
pages = "291--295",
journal = "Biotherapy",
issn = "0914-2223",
publisher = "Japanese Society for Cancer Chemotherapy",
number = "4",

}

TY - JOUR

T1 - Molecular targeted drugs and immunity

AU - Morisaki, Takashi

AU - Ohnishi, Hideya

AU - Suzuki, Hiroyuki

AU - Katano, Mitsuo

PY - 2010/7

Y1 - 2010/7

N2 - Molecular targeted therapy was largely developed as a consequence of advances in the understanding of the molecular biology of cancer. It was also developed in response to the challenge of optimizing antitumor activity while decreasing nonspecific toxicity. Besides the direct effect on tumor cells, several molecular targeted drugs have been shown to modulate immune responses against cancer including the decreasing number of regulatory T cells (Treg) and activating NK cells. In this review, we focus on recent reports which show the interaction of molecular targeted drugs with immune response. In the near future, combinations of molecular targeted drugs with new immunotherapeutic approaches might become a reality.

AB - Molecular targeted therapy was largely developed as a consequence of advances in the understanding of the molecular biology of cancer. It was also developed in response to the challenge of optimizing antitumor activity while decreasing nonspecific toxicity. Besides the direct effect on tumor cells, several molecular targeted drugs have been shown to modulate immune responses against cancer including the decreasing number of regulatory T cells (Treg) and activating NK cells. In this review, we focus on recent reports which show the interaction of molecular targeted drugs with immune response. In the near future, combinations of molecular targeted drugs with new immunotherapeutic approaches might become a reality.

UR - http://www.scopus.com/inward/record.url?scp=77955819977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955819977&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:77955819977

VL - 24

SP - 291

EP - 295

JO - Biotherapy

JF - Biotherapy

SN - 0914-2223

IS - 4

ER -